Works Cited

1. English JF, Cundiff MY, Malone JD, et al. Bioterrorism Readiness Plan: A Template for Healthcare Facilities. Washington, DC: Association for Professionals in Infection Control and Epidemiology; 1999.

2. Centers for Disease Control and Prevention. Travelers' Health: Anthrax. Available at https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/anthrax. Last accessed August 18, 2020.

3. Placer County Health and Human Services and Placer/Nevada County Medical Society. Zebra Primer on Bioterrorism. Auburn, CA: Placer County Health and Human Services; 2001.

4. Crutcher M. Response to biological terrorism. Paper presented at: Epidemiologists and Professionals in Infection Control (EPIC) Meeting; May 2000, Oklahoma City, OK.

5. Federal Bureau of Investigation. Amerithrax or Anthrax Investigation. Available at https://archives.fbi.gov/archives/about-us/history/famous-cases/anthrax-amerithrax. Last accessed August 18, 2020.

6. Office of the Secretary of Defense. Proliferation: Threat and Response Briefing. Available at https://fas.org/irp/threat/prolif97/t11251997_t1125ptr.html. Last accessed August 18, 2020.

7. San Francisco Department of Public Health. Recognizing Bioterrorism. Available at https://www.sfcdcp.org/health-alerts-emergencies/recognize-an-illness-associated-with-bioterrorism. Last accessed August 18, 2020.

8. Audi J, Belson M, Patel M, Schier J, Osterloh J. Ricin poisoning: a comprehensive review. JAMA. 2005;294(18):2342-2351.

9. Dembek ZF, Alves DA, Cieslak TJ, et al. (eds). USAMRIID's Medical Management of Biological Casualties Handbook. 7th ed. Fort Detrick, MD: U.S. Army Medical Research; 2011.

10. Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci USA. 2005;102(28):9984-9989.

11. Dembek ZF. Medical Aspects of Biological Warfare. Washington, DC: TMM Publications; 2007.

12. Weber DJ, Sickbert-Bennett E, Gergen MF, Rutala WA. Efficacy of selected hand hygiene agents used to remove Bacillus atrophaeus (a surrogate of Bacillus anthracis) from contaminated hands. JAMA. 2003;289(10):1274-1277.

13. Katzman K. Iraq: Weapons Programs, U.N. Requirements, and U.S. Policy. Available at https://digital.library.unt.edu/ark:/67531/metacrs4231/m1/1/high_res_d/IB92117_2003Mar26.pdf. Last accessed August 18, 2020.

14. Inglesby TV, O'Toole T, Henderson DA, et al.; Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA. 2002;287(17):2236-2252.

15. Centers for Disease Control and Prevention. Anthrax: Basic Information. Available at https://www.cdc.gov/anthrax/basics/index.html. Last accessed August 14, 2020.

16. Wright JG, Quinn CP, Shadomy S, Messonnier N; Centers for Disease Control and Prevention. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR. 2010;59(RR6):1-30.

17. Centers for Disease Control and Prevention. Yellow Book: Chapter 3: Infectious Diseases Related to Travel. Available at https://wwwnc.cdc.gov/travel/yellowbook/2020/table-of-contents. Last accessed August 18, 2020.

18. Johnson S. Response to bioterrorism: the role of laboratories. Paper presented at: Epidemiologists and Professionals in Infection Control (EPIC) Meeting; August 17, 2000; Oklahoma City, OK.

19. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis. 2008;14(4).

20. Centers for Disease Control and Prevention. Anthrax: Recommended Specimens for Microbiology and Pathology for Diagnosis of Anthrax. Available at https://www.cdc.gov/anthrax/specificgroups/lab-professionals/recommended-specimen.html. Last accessed August 18, 2020.

21. Centers for Disease Control and Prevention. Recommended Specimens for Microbiology and Pathology for Diagnosis of Anthrax. Available at https://wwwn.cdc.gov/nndss/conditions/anthrax/case-definition/2010. Last accessed August 14, 2020.

22. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR. 2001;50(42):909-919.

23. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2).

24. Jang KH, Nam S-J, Locke JB, et al. Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete. Angew Chem Int Ed Engl. 2013;52(30):7822-7824.

25. Barclay L. Anthrax Guidelines Address Nonpregnant, Pregnant Adults. Available at https://www.medscape.com/viewarticle/819274. Last accessed August 18, 2020.

26. Alexander JJ, Colangelo PM, Cooper CK, Roberts R, Rodriguez WJ, Murphy MD. Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations. Pediatr Infect Dis J. 2008;27(11):955-957.

27. U.S. Food and Drug Administration. FDA Approves Treatment for Inhalation Anthrax. Available at https://wayback.archive-it.org/7993/20170405005211/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm. Last accessed August 18, 2020.

28. Advisory Committee on Immunization Practices. Notice to readers: use of anthrax vaccine in the response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR. 2002;51(45):1024-1026.

29. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. JAMA. 2000;283(17):2281-2290.

30. Centers for Disease Control and Prevention. Plague Training Module. Available at https://emergency.cdc.gov/agent/plague/publications-training.asp. Last accessed August 18, 2020.

31. Centers for Disease Control and Prevention. Plague. Available at https://www.cdc.gov/plague. Last accessed August 18, 2020.

32. Wheelis M. Biological warfare at the 1346 siege of Caffa. Emerg Infect Dis. 2002;8(9):971-975.

33. Centers for Disease Control and Prevention. Frequently Asked Questions about Plague. Available at https://emergency.cdc.gov/agent/plague/faq.asp. Last accessed August 18, 2020.

34. Heymann DL (ed). Control of Communicable Disease Manual. 20th ed. Washington, DC: American Public Health Association; 2014.

35. Centers for Disease Control and Prevention. Plague: Diagnosis and Evaluation. Available at https://emergency.cdc.gov/agent/plague/diagnosis.asp. Last accessed August 14, 2020.

36. Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis. 2005;40(8):1166-1172.

37. Sha J, Endsley JJ, Kirtley ML, et al. Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks.J Clin Microbiol. 2011;49(5):1708-1715.

38. Friedlander AM, Welkos SL, Worsham PL, et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin Infect Dis. 1995;21(Suppl 2):S178-S181.

39. Centers for Disease Control and Prevention. Plague: Resources for Clinicians. Available at https://www.cdc.gov/plague/healthcare/clinicians.html. Last accessed August 14, 2020.

40. Jefferson T, Demicheli V, Pratt M. Vaccines for preventing plague. Cochrane Database Syst Rev. 2000(2):CD000976.

41. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA. 2001;285(21):2763-2773.

42. Centers for Disease Control and Prevention. Francisella tularensis (Tularemia). Available at https://emergency.cdc.gov/agent/tularemia/facts.asp. Last accessed August 14, 2020.

43. World Health Organization. Health Aspects of Chemical and Biological Weapons: Report of a WHO Group of Consultants. Geneva: World Health Organization; 1970.

44. Sacramento County Public Health Division. Medical Treatment and Response to Suspected Tularemia: Information for Health Care Providers During Biologic Emergencies. Available at https://dhs.saccounty.net/PUB/Documents/PUB_ZTularemia.pdf. Last accessed August 18, 2020.

45. Cleveland KO. Tularemia. Available at https://emedicine.medscape.com/article/230923-overview. Last accessed August 18, 2020.

46. Penn RL. Francisella tularensis (tularemia). In: Bennet JE, Dolin R, Blaser MJ (eds). Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. New York, NY: Saunders; 2014: 2060-2068.

47. County of Los Angeles Department of Public Health and the Emergency Medical Services Agency of the Los Angeles County Department of Health Services. Terrorism Agent Information and Treatment Guidelines for Clinicians and Hospitals. Los Angeles, CA: County of Los Angeles Public Health; 2012.

48. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Cin Infect Dis. 2014;59(2):e10-e52.

49. Hofinger DM, Cardona L, Mertz GJ, Davis LE. Tularemic meningitis in the United States. Arch Neurol. 2009;66(4):523-527.

50. Lamps LW, Havens JM, Sjostedt A, Page DL, Scott MA. Histologic and molecular diagnosis of tularemia: a potential bioterrorism agent endemic to North America. Mod Pathol. 2004;17(5):489-495.

51. French GR, Plotkin SA. Miscellaneous limited-use vaccines. In: Plotkin S, Orenstein W, Offit PA (eds). Vaccines. 6th ed. Philadelphia, PA: Saunders; 2012: 728-733.

52. Oyston PCF, Quarry JE. Tularemia vaccine: past, present, and future. Antoine van Leeuwenhoek. 2005;87(4):277-281.

53. Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann Intern Med. 1997;127(8): 635-642.

54. Dowd GE. War Under Heaven: Pontiac, the Indian Nations, & the British Empire. Baltimore, MD: Johns Hopkins University Press; 2004.

55. Brennan JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med. 2002;346(17):1300-1308.

56. Alibek K, Handelman S. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World. New York, NY: Random House; 1999.

57. Fenner F, Henderson DA, Arita A, Jezek Z, Ladnyl ID. Smallpox and its Eradication. Geneva: World Health Organization; 1988.

58. Centers for Disease Control and Prevention. Acute, Generalized Vesicular or Pustular Rash Illness Protocol in the United States. Available at https://www.cdc.gov/smallpox/pdfs/rash-illness-protocol.pdf. Last accessed August 18, 2020.

59. Centers for Disease Control and Prevention. Smallpox: Diagnosis and Evaluation. Available at https://www.cdc.gov/smallpox/clinicians/diagnosis-evaluation.html. Last accessed August 14, 2020.

60. Centers for Disease Control and Prevention. Smallpox: Detection and Response. Available at https://www.cdc.gov/smallpox/bioterrorism/public/detection-response.html. Last accessed August 14, 2020.

61. Texas Department of Health. Emergency Preparedness and Response. Available at https://www.texascountyhealth.org/Emergency%20Preparedness.aspx. Last accessed August 18, 2020.

62. Centers for Disease Control and Prevention. Specimen Collection and Transport Guidelines for Suspect Smallpox Cases. Available at https://www.cdc.gov/smallpox/lab-personnel/specimen-collection/specimen-collection-transport.html. Last accessed August 18, 2020.

63. World Health Organization. Smallpox. Available at https://www.who.int/csr/disease/smallpox/en. Last accessed August 18, 2020.

64. Centers for Disease Control and Prevention. Smallpox: Vaccine Basics. Available at https://www.cdc.gov/smallpox/vaccine-basics/index.html. Last accessed August 14, 2020.

65. Lanier R, Trost L, Tippin T, et al. Development of CMX001 for the treatment of poxvirus infections. Viruses. 2010;2(12):2740-2762.

66. Centers for Disease Control and Prevention. Smallpox. Medical Management of Adverse Reactions. Available at https://www.cdc.gov/smallpox/clinicians/vaccine-medical-management6.html. Last accessed August 18, 2020.

67. MedlinePlus. Cidofovir Injection. Available at https://medlineplus.gov/druginfo/meds/a696037.html. Last accessed August 18, 2020.

68. University of Maryland Medical Center. Smallpox. Available at https://health.umd.edu/sites/default/files/inline-files/Important%20Information%20About%20Vaccinia%20%28Smallpox%29%20Vaccine.pdf. Last accessed August 18, 2020.

69. U.S. Food and Drug Administration. Questions About Vaccines: Smallpox. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/smallpox. Last accessed August 18, 2020.

70. Hatch GJ, Graham VA, Bewley KR, et al. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J Virol. 2013;87(14):7805-7815.

71. U.S. Food and Drug Administration. ACAM2000 (Smallpox Vaccine) Questions and Answers. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000-smallpox-vaccine-questions-and-answers. Last accessed August 18, 2020.

72. Bavarian Nordic. Bavarian Nordic Completes Delivery of 20 Million Doses of IMVAMUNE Smallpox Vaccine to the U.S. Strategic National Stockpile. Available at https://www.bavarian-nordic.com/investor/news/news.aspx?news=3051. Last accessed August 18, 2020.

73. Centers for Disease Control and Prevention. Smallpox. Vaccination. Available at https://www.cdc.gov/smallpox/clinicians/vaccination.html. Last accessed August14, 2020.

74. LexiComp Online. Available at https://online.lexi.com. Last accessed August 18, 2020.

75. Petersen BW, Damon IK, Pertowski CA, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program. MMWR. 2015;64(RR02):1-26.

76. Centers for Disease Control and Prevention. Smallpox: Ring Vaccination. Available at https://www.cdc.gov/smallpox/bioterrorism-response-planning/public-health/ring-vaccination.html. Last accessed August 14, 2020.

77. Borio L, Inglesby TV, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA. 2002;287(18):2391-2405.

78. U.S. Army Medical Research and Materiel Command. Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities. Available at https://clinicaltrials.gov/ct2/show/NCT00992693. Last accessed August 18, 2020.

79. World Health Organization. Application for Inclusion of Ribavirin in the WHO Model List of Essential Medicines. Available at http://archives.who.int/eml/expcom/expcom15/applications/newmed/ribaravin/ribavirin.pdf. Last accessed August 18, 2020.

80. Centers for Disease Control and Prevention. Interim Guidance for Managing Patients with Suspected Viral Hemorrhagic Fever in U.S. Hospitals. Available at https://www.cdc.gov/hai/pdfs/bbp/vhfinterimguidance05_19_05.pdf. Last accessed August 18, 2020.

81. U.S. Food and Drug Administration. Emergency Investigational New Drug (EIND) Applications for Antiviral Products. Available at https://www.fda.gov/drugs/investigational-new-drug-ind-application/emergency-investigational-new-drug-eind-applications-antiviral-products. Last accessed August 18, 2020.

82. California Department of Industrial Relations, Division of Occupational Safety and Health. Interim Guidance on Ebola Virus in Inpatient Hospital Settings. Available at https://www.dir.ca.gov/dosh/documents/Cal-OSHA-Guidance-on-Ebola-Virus.pdf. Last accessed August 18, 2020.

83. Centers for Disease Control and Prevention. Guidance on Personal Protective Equipment (PPE) To Be Used By Healthcare Workers during Management of Patients with Confirmed Ebola or Persons under Investigation (PUIs) for Ebola who are Clinically Unstable or Have Bleeding, Vomiting, or Diarrhea in U.S. Hospitals, Including Procedures for Donning and Doffing PPE. Available at https://www.cdc.gov/vhf/ebola/healthcare-us/ppe/guidance.html. Last accessed August 18, 2020.

84. Public Health Agency of Canada. Clostridium botulinum. Available at https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/clostridium-botulinum.html. Last accessed August 18, 2020.

85. Frantz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. 1997;278(5):399-411.

86. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge. JAMA. 1997;278(5):433-435.

87. Alguire P (ed). ACP bioterrorism resource guide. ACP Observer. 2004;5.

88. Villar RG, Elliott SP, Davenport KM. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am. 2006;20(2):313-327.

89. Centers for Disease Control and Prevention. Botulism: Information for Health Professionals. Available at https://www.cdc.gov/botulism/health-professional.html. Last accessed August 14, 2020.

90. Centers for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR. 2010;59(10):299.

91. U.S. Food and Drug Administration. FDA Approves First Botulinum Antitoxin for Use in Neutralizing All Seven Known Botulinum Nerve Toxin Serotypes. Available at https://wayback.archive-it.org/7993/20161022134538/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm. Last accessed August 18, 2020.

92. Varma JK, Katsitadze G, Moiscrafishvili M, et al. Signs and symptoms predictive of death in patients with foodborne botulism—Republic of Georgia, 1980–2002. Clin Infect Dis. 2004;39(3):357-362.

93. Centers for Disease Control and Prevention. Investigation of a ricin-containing envelope at a postal facility—South Carolina, 2003. MMWR. 2003;52(46):1129-1131.

94. Shea D, Gottron F. CRS Report for Congress. Ricin: Technical Background and Possible Role in Terrorism. Washington, DC: Library of Congress; 2004.

95. Centers for Disease Control and Prevention. Health Advisory: CDC Alert on Ricin. Available at https://emergency.cdc.gov/agent/ricin/han_022008.asp. Last accessed August14,2020.

96. Centers for Disease Control and Prevention. Ricin: Epidemiological Overview for Clinicians. Available at https://emergency.cdc.gov/agent/ricin/clinicians/epidemiology.asp. Last accessed August 14, 2020.

97. Centers for Disease Control and Prevention. Bioterrorism Agents/Diseases. Available at https://emergency.cdc.gov/agent/agentlist.asp. Last accessed August 14, 2020.

98. U.S. Department of Health and Human Services Office of Public Health Emergency Preparedness. Response to a Ricin Incident: Guidelines for Federal, State, and Local Public Health and Medical Officials. Washington, DC: Department of Health and Human Services; 2006.

99. U.S. Army Medical Research and Material Command. USAMRIID Begins Clinical Trial of New Vaccine to Protect Against Ricin Toxin. Available at https://www.usamriid.army.mil/press_releases/Ricin%20News%20Release%2013%20Apr%202011.pdf. Last accessed August 18, 2020.

100. O'Hara JM, Brey RN 3rd, Mantis NJ. Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.Clin Vaccine Immunol. 2013;20(6):789-794.

101. Soligenix. Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine. Available at https://www.prnewswire.com/news-releases/soligenix-receives-additional-niaid-funding-to-advance-development-of-heat-stable-ricin-vaccine-300476933.html. Last accessed August 18, 2020.

102. Brey RN III, Mantis NJ, Pincus SH, Vitetta ES, Smith LA, Roy CJ. Recent advances in the development of vaccines against. Ricin. Hum Vaccin Immunother. 2016;12(5):1196-1201.

103. Centers for Disease Control and Prevention. Emergency Preparedness and Response. Available at https://emergency.cdc.gov. Last accessed August 14,2020.

104. Association for Professionals in Infection Control and Epidemiology. Available at https://apic.org. Last accessed August 18, 2020.

105. Hwa-Froelich DA, Westby CE. Considerations when working with interpreters. Commun Disord Q. 2003;4(2):78-85.

106. U.S. Food and Drug Administration. FDA Approves the First Drug with an Indication for Treatment of Smallpox. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-indication-treatment-smallpox. Last accessed August 18, 2020.

107. U.S. Food and Drug Administration. FDA Approves First Live, Non-Replicating Vaccine to Prevent Smallpox and Monkeypox. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox. Last accessed August 18, 2020.

108. Centers for Disease Control and Prevention. Anthrax: Bioterrorism: The Threat. Available at https://www.cdc.gov/anthrax/bioterrorism/threat.html. Last accessed August 14, 2020.

109. Centers for Disease Control and Prevention. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident: recommendations and reports. MMWR. 2015;64(RR4):1-28.

110. Centers for Disease Control and Prevention. Considerations for Anthrax Vaccine Adsorbed (AVA) Post-Exposure Prioritization Final. Available at https://www.cdc.gov/anthrax/pdf/ava-post-event-prioritization-guidance.pdf. Last accessed August 18, 2020.

111. Boulanger LL, Ettestad P, Fogarty JD, et al. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in New Mexico, 1985–1999. Clin Infect Dis. 2004;38:663-669.

112. Meyer H, Ehmann R, Smith GL. Smallpox in the post-eradication era. Viruses. 2020;12:138.

113. Grosenbach DW, Honeychurch K, Rose E, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379:44-53.

Evidence-Based Practice Recommendations Citations

1. Pfefferbaum B, Shaw JA, American Academy of Child and Adolescent Psychiatry Committee on Quality Issues. Practice parameter on disaster preparedness. J Am Acad Child Adolesc Psychiatry. 2013;52(11):1224-1238. Available at https://www.jaacap.org/article/S0890-8567(13)00550-9/pdf. Last accessed August 21, 2020.


Copyright © 2020 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.